CVRx touts positive two-year data for heart failure neuromodulation device

Building on long-term data announced earlier this year, CVRx has reported durable improvements in heart failure patients with its Barostim device over 24 months.

The results, published in the Journal of the American College of Cardiology: Heart Failure, demonstrated that patients implanted with the Barostim reported feeling significantly better in a variety of physical and psychosocial measures.